ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > FDA decision will have waterfall effect on other companies

<< Previous

Bullboard Posts

Next >>

Comment by Annayyaon Jun 02, 2021 3:00pm

97 Views

Post# 33312240

RE:FDA decision will have waterfall effect on other companies

What do you think will be the effect on PMN. There are numerous articles comparing PMN to Biogen. Could PMN share price double with our best in class approach? I am hoping that the approval news comes before June 7th, preferably on June 4th. I don't like the suspense on a Monday morning and want to get it over with this week.